NEW YORK – Metrion Biosciences, an ion channel research and drug discovery company based in the UK, said Wednesday that it has secured £3.5 million ($4.7 million) in new equity financing, including £2.5 million from lead investor Maven Capital Partners and £1 million from its prior investor Gresham House Ventures.
The company said it will use the funding to expand its laboratories in Cambridge, invest in new specialist equipment, and enhance its global marketing activities.
The latest funding comes after Metrion raised £2.7 million in equity financing in 2021, including £2.3 million from Gresham House Ventures.